Salicylamide inhibitors of influenza virus fusion

Bioorg Med Chem Lett. 2000 Aug 7;10(15):1649-52. doi: 10.1016/s0960-894x(00)00335-8.

Abstract

Structural variation of the quinolizidine heterocycle of the influenza fusion inhibitor BMY-27709 was examined by several topological dissections in order to illuminate the critical features of the ring system. This exercise resulted in the identification of a series of synthetically more accessible decahydroquinolines that retained the structural elements of BMY-27709 important for antiviral activity. The 2-methyl-cis-decahydroquinoline 6f was the most potent influenza inhibitor identified that demonstrated an EC50 of 90 ng/mL in a plaque reduction assay.

MeSH terms

  • Animals
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology*
  • Cell Line
  • Dogs
  • Membrane Fusion / drug effects*
  • Orthomyxoviridae / drug effects*
  • Orthomyxoviridae / physiology
  • Quinolizines / chemistry
  • Quinolizines / pharmacology*
  • Salicylamides / chemistry
  • Salicylamides / pharmacology*

Substances

  • Antiviral Agents
  • BMY 27709
  • Quinolizines
  • Salicylamides
  • salicylamide